ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Abatacept"

  • Abstract Number: 563 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of Abatacept in Combination with MTX in Early, MTX-Naïve, Anti-Citrullinated Protein Antibody–Positive Patients with RA: Primary and 1-Year Results from a Phase IIIb Study

    Paul Emery1, Yoshiya Tanaka2, Vivian P. Bykerk3, Tom W.J. Huizinga4, Gustavo Citera5, Marleen Nys6, Sean E. Connolly7, Alyssa Johnsen7 and Roy Fleischmann8, 1University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Hospital for Special Surgery, New York, NY, 4Leiden University Medical Center, Leiden, Netherlands, 5Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 6Bristol-Myers Squibb, Braine L’Alleud, Belgium, 7Bristol-Myers Squibb, Princeton, NJ, 8Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: In patients (pts) with early (disease duration ≤24 months [mths]), MTX-naïve RA and poor prognostic factors including anti-citrullinated protein antibody (ACPA) positivity (+), abatacept…
  • Abstract Number: 900 • 2018 ACR/ARHP Annual Meeting

    Abatacept Vs. Placebo in Early Diffuse Cutaneous Systemic Sclerosis— Results of a Phase 2 Investigator Initiated, Double-Blind, Placebo-Controlled, Multicenter, Randomized Controlled Trial Study

    Dinesh Khanna1, Cathie Spino2, Erica Bush3, Sindhu Johnson4, Lorinda Chung5, Jerry Molitor6, Virginia D. Steen7, Robert Lafyatis8, Robert W. Simms9, Christopher P. Denton10, Suzanne Kafaja11, Tracy M. Frech12, Vivien Hsu13, Robyn T. Domsic14, Janet E. Pope15, Jessica K. Gordon16, Maureen D. Mayes17, Elena Schiopu3, Amber Young1, Nora Sandorfi18, Jane Park19, Faye N. Hant20, Elana J. Bernstein21, Soumya Chatterjee22, Flavia V. Castelino23, Ali Ajam24, Yannick Allanore25, Marco Matucci-Cerinic26, Oliver Distler27, Ora Singer28, Haoyan Zhong2, David Fox29 and Daniel E. Furst30, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 2Biostatistics, University of Michigan, Ann Arbor, MI, 3University of Michigan, Ann Arbor, MI, 4Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 5Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 6Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, 7Rheumatology, MedStar Georgetown University Hospital, Washington, DC, 8Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, 9Rheumatology, Boston University School of Medicine, Boston, MA, 10UCL Division of Medicine, Royal Free Campus, London, United Kingdom, 11Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, 12Division of Rheumatology, University of Utah, Salt Lake City, UT, 13Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, 14Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 15Department of Medicine, University of Western Ontario, London, ON, Canada, 16Rheumatology, Hospital for Special Surgery, New York, NY, 17Rheumatology, University of Texas McGovern Medical School, Houston, TX, 18Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, 19Seattle Rheumatology Associates, Seattle, WA, 20Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 21Rheumatology, Columbia University, New York, NY, 22Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 23Rheumatology, Harvard Medical School, Boston, MA, 24Division of Rheumatology-Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, 25Service de Rhumatologie A, Hôpital Cochin, Paris, France, 26Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 27Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 28Medicine, University of Michigan, Ann Arbor, MI, 29Internal Medicine, University of Michigan, Ann Arbor, MI, 30UCLA, Los Angeles, CA

    Background/Purpose: Abatacept (ABA) is a recombinant fusion protein including extracellular domain of human CTLA4 and hinge‑ CH2‑CH3 of the Fc domain of human IgG. This…
  • Abstract Number: 971 • 2018 ACR/ARHP Annual Meeting

    A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept or Placebo on Standard of Care in Patients with Active Class III or IV Lupus Nephritis

    Mary A. Dooley1, Gerald B. Appel2, Richard Furie3, David Wofsy4, Tsutomu Takeuchi5, Ana Malvar6, Andrea Doria7, Juanita Romero-Díaz8, Tak Mao Chan9, Ayanbola Elegbe10, David Jayne11 and Michael A. Maldonado10, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Columbia University Medical Center, New York, NY, 3Northwell Health, New York, NY, 4University of California San Francisco, San Francisco, CA, 5Keio University School of Medicine, Tokyo, Japan, 6Nephrology Division, Hospital Fernández, Buenos Aires, Argentina, 7Division of Rheumatology, University of Padova, Padova, Italy, 8Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, 9University of Hong Kong, Hong Kong, Hong Kong, 10Bristol-Myers Squibb, Princeton, NJ, 11University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: The tenets of novel treatment (tx) strategies for active class III/IV lupus nephritis (LN) aim to improve renal response rates, decrease extra-renal SLE disease…
  • Abstract Number: 1105 • 2018 ACR/ARHP Annual Meeting

    Abatacept Is Effective in Experimental Digestive and Lung Tissue Fibrosis

    Gonçalo Boleto1, Christophe Guignabert2, Sonia Pezet3, Anne Cauvet3, Jérémy Sadoine4, Ly Tu2, Carole Nicco3, Camille Gobeaux5, Frederic Batteux3, Yannick Allanore3 and Jérôme Avouac1, 1Université Paris Descartes, Sorbonne Paris Cité, Service de Rhumatologie A, Hôpital Cochin, Paris, France, Paris, France, 2INSERM UMR_S 999, Le Plessis-Robinson, France, Le Plessis-Robinson, France, 3Université Paris Descartes, Sorbonne Paris Cité, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France, Paris, France, 4EA 2496 Pathologie, Imagerie et Biothérapies Orofaciales, UFR Odontologie, Université Paris Descartes and PIDV, PRES Sorbonne Paris Cité, Montrouge, France, Montrouge, France, 5Clinical Chemistry Laboratory, Cochin and Hôtel-Dieu Hospitals, Paris, France, Paris, France

    Background/Purpose: A previous report showed that abatacept (IgG-CTLA-4) prevented and induced regression of inflammation-driven dermal fibrosis in two different mouse models of systemic sclerosis (SSc)…
  • Abstract Number: 1543 • 2018 ACR/ARHP Annual Meeting

    The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis

    Takuma Tsuzuki Wada1, Yu Funakubo Asanuma2, Mayumi Matsuda3, Hiroaki Yazawa2, Yoshinobu Nakao4, Noritsune Kozu5 and Toshihide Mimura2, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 3Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 4Department of Rheumatology, Saga University Hospital, Saga, Japan, 5Kozu Orthopedic Clinic, Yachiyo, Japan

    Background/Purpose: Elderly patients with rheumatoid arthritis (RA) have declined physical performances and increased various complications. We are concerned about decrease of efficacy and increase of…
  • Abstract Number: 1716 • 2018 ACR/ARHP Annual Meeting

    Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis in a Phase II Trial of Abatacept Vs. Placebo

    Dinesh Khanna1 and Cathie Spino2, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 2Biostatistics, University of Michigan, Ann Arbor, MI

    Background/Purpose: Treatment with CTLA4Ig, abatacept (ABA), in early diffuse cutaneous systemic sclerosis (dcSSc; the Phase 2 ASSETtrial) showed evidence of improvements in modified Rodnan skin…
  • Abstract Number: 2378 • 2018 ACR/ARHP Annual Meeting

    Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category

    Nicola Ruperto1, Hermine I. Brunner2, Gabriel Vega-Cornejo3, Alberto Berman4, Rubén J. Cuttica5, Francisco Ávila-Zapata6, Michael Henrickson7, Daniel J Kingsbury8, John F. Bohnsack9, Thomas Lutz10, Nadina E Rubio-Pérez11, Valeria Gerloni12, Xiaohui Li13, Marleen Nys14, Robert Wong13, Alberto Martini15 and Daniel J Lovell16, 1Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia, Genoa, Italy, 2Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, 4Centro Médico Privado de Reumatología, Tucumán, Argentina, 5Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, 6Star Medica Hospital, Merida, Yucatán, Mexico, 7Cincinnati Children’s Medical Center, Cincinnati, OH, 8Randall Children’s Hospital at Legacy Emanuel, Portland, OR, 9University of Utah School of Medicine, Salt Lake City, UT, 10Pediatric Rheumatology, University Hospital, Center for Pediatric and Adolescent Medicine / Clinic 1, Heidelberg, Germany, 11Universidad Autónoma de Nuevo León, Monterrey Nuevo León, Mexico, 12Istituto Gaetano Pini, Milan, Italy, 13Bristol-Myers Squibb, Princeton, NJ, 14Bristol-Myers Squibb, Braine L’Alleud, Belgium, 15Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy, 16Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: The effect of biologic DMARDs on different juvenile idiopathic arthritis (JIA) categories is poorly understood. In patients (pts) with JIA aged 2–17 years (y),…
  • Abstract Number: 2452 • 2017 ACR/ARHP Annual Meeting

    In Real-World Clinical Practice, Patients Switching from IV to SC Abatacept Maintain Clinical Efficacy after Switch

    Rieke Alten1, HM Lorenz2, X Mariette3, H Nüßlein4, M Galeazzi5, F Navarro6, M Chartier7, J Heitzmann8, C Rauch9 and M Le Bars7, 1Schlosspark-Klinik University Medicine, Berlin, Germany, 2University Hospital, Heidelberg, Germany, 3Université Paris-Sud, Paris, France, 4University of Erlangen-Nuremberg, Nuremberg, Germany, 5University of Siena, Siena, Italy, 6Hospital Universitario Virgen Macarena, Seville, Spain, 7Bristol-Myers Squibb, Rueil-Malmaison, France, 8Excelya, Boulogne-Billancourt, France, 9Bristol-Myers Squibb, Munich, Germany

    Background/Purpose: Patients (pts) with RA may be able to switch from IV to SC abatacept with no loss of efficacy or safety concerns, but data…
  • Abstract Number: 419 • 2017 ACR/ARHP Annual Meeting

    Abatacept Initiation in Chilean Patients with Long Lasting Rheumatoid Arthritis. Hospital Padre Hurtado Experience

    Omar Valenzuela1, María Paz Poblete2, Claudia Mardones2, Sebastián Ibáñez1, Katherine Mogollones2, Francisco Silva1 and María José Villar2, 1Rheumatology department, Hospital Padre Hurtado, Santiago, Chile, 2Hospital Padre Hurtado, Santiago, Chile

    Background/Purpose: Since the year 2016 Rheumatoid Arthritis (RA) patients in the Chilean public health system can access biologic treatment if they have active disease refractory…
  • Abstract Number: 2491 • 2017 ACR/ARHP Annual Meeting

    Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive Vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study

    B Haraoui1, Janet E. Pope2, Isabelle Fortin3, Emmanouil Rampakakis4, John S. Sampalis5,6, Francoise Romeyer7, Joseph Atallah7 and Louis Bessette8, 1Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, 2Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 3Centre de Rhumatologie de l'Est du Quebec, Rimouski, QC, Canada, 4JSS Medical Research, Montreal, QC, Canada, 5McGill University, Montreal, QC, Canada, 6JSS Medical Research, St-Laurent, QC, Canada, 7Bristol-Myers Squibb, Montreal, QC, Canada, 8Centre d'Osteoporose et de Rhumatologie de Quebec, Quebec, QC, Canada

    Background/Purpose: The efficacy and safety of subcutaneous (SC) abatacept in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. However,…
  • Abstract Number: 498 • 2017 ACR/ARHP Annual Meeting

    Response to Abatacept of Different Patterns of Interstitial Lung Disease in Rheumatoid Arthritis. Multicenter Study of 63 Patients

    Carlos Fernández-Díaz1, Santos Castañeda2, Clara Ojeda-Garcia3, Alejandro Olivé4, Patricia Carreira5, Trinidad Perez Sandoval6, Miriam Retuerto Guerrero7, Evelin Cecilia Cervantes Pérez8, Samantha Rodriguez9, Bryan Josue Robles Flores10, Blanca Hernández-Cruz11, Ana Urruticoechea-Arana12, Olga Maiz13, Desiree Palma14, Luis Arboleya15, Gema Bonilla16, Manuel Rodríguez-Gómez17, Concepción Delgado18, Rosa Expósito19, Ana Ruibal Escribano20, Juan Blanco Madrigal21, José Antonio Bernal22, Paloma Vela23, Belen Alvarez-Rodriguez24, María Concepción Fito Manteca25, Javier Narváez26, Manuel Jose Moreno27, Mireia López-Corbeto28, Natalia Mena-Vazquez29, S. Romero-Yuste30, Clara Aguilera-Cros31, Sergi Ordoñez32, Ignacio Villa-Blanco33, Nuria Vegas-Revenga1, Victor Mora-Cuesta34, Javier Loricera1, Miguel Angel González-Gay1, José Luis Hernandez35 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario de La Princesa, Madrid. Spain, Madrid, Spain, 3Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, 4Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 5Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 6Rheumatology, Hospital de León, LEÓN, Spain, 7Rheumatology, Hospital de León, Leon, Spain, 8Rheumatology, Hospital Santiago de Compostela, Santiago de Compostela, Spain, 9H. German Trias., Barcelona, Spain, 10Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 11Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, 12Rheumatology Department. Hospital Can Misses, IBIZA, Spain, 13Hospital Donostia. Spain, San Sebastian, Spain, 14Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, 15Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, 16Hospital Universitario La Paz, Madrid, Spain, 17Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 18H. Clínico Universitario Lozano Blesa, Zaragoza, Spain, 19Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, 20Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, 21Rheumatology, Hospital de Basurto, BIlbao, Spain, 22Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, 23Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, 24Hospital Txagorritxu, Vittoria, Spain, 25Reumatología, Hospital de Navarra, Pamplona, Spain, 26Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, 27Rheumatology, Hospital Virgen de la Arrixaca, MURCIA, Spain, 28Hospital Universitario Vall d´Hebron, Barcelona, Spain, 29Rheumatology, Hospital Universitario de Malaga, Malaga, Spain, 30H. Pontevedra, Pontevedra, Spain, 31Rheumatology, Hospital Virgen del Rocio, Sevilla, Spain, 32Hospital Universitario Arnau de Vilanova, Vilanova, Spain, 33Hospital de Sierrallana, Sierrallana, Spain, 34Neumology, Hospital Universitario Marqués de Valdecilla, IDIVAL,, Santander, Spain, 35Division of Internal Medicine., Hospital Universitario Marqués de Valdecilla, IDIVAL,, Santander, Spain

    Background/Purpose: Disease modifying antirheumatic drugs (DMARD) such as methotrexate (MTX), ) or antiTNFα have been implicated in exacerbation of Interstitial lung disease (ILD)of rheumatoid arthritis…
  • Abstract Number: 2494 • 2017 ACR/ARHP Annual Meeting

    Analysis of the Efficacy, Safety and Continuation Rate of Abatacept in Elderly Patients with Rheumatoid Arthritis

    Mayumi Matsuda1, Yu Funakubo Asanuma2, Noritsune Kouzu3 and Toshihide Mimura2, 1Department of Rheumatology and Applied Immunology, Saitama Medical University, Moroyama-machi, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 3Saitama Medical University, Moroyama, Japan

    Background/Purpose: The elderly rheumatoid arthritis (RA) patients have declined physical performances and various complications. The efficacy of the biological DMARDs may decrease in elderly RA…
  • Abstract Number: 526 • 2017 ACR/ARHP Annual Meeting

    Comparative Pulmonary Safety of Abatacept and Tumor Necrosis Factor Inhibitors in Patients with RA and Chronic Pulmonary Condition

    Eun Ha Kang1, Yinzhu Jin2, Sara Dejene3, Gregory Brill3, Rishi J. Desai2, Jeffrey A. Sparks4 and Seoyoung C. Kim5, 1Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Patients with rheumatoid arthritis (RA) can have various pulmonary comorbidities including asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Biologics can…
  • Abstract Number: 2786 • 2017 ACR/ARHP Annual Meeting

    Timing of Abatacept Infusions before Elective Arthroplasty and the Risk of Post-Operative Infection

    Michael D. George1, Joshua Baker2, Kevin Winthrop3, E Alemao4, Lang Chen5, SE Connolly4, TA Simon4, Qufei Wu6, Fenglong Xie7, Shuo Yang7 and Jeffrey R. Curtis8, 1Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Rheumatology, University of Pennsylvania, Philadelphia, PA, 3Oregon Health Sciences University, Portland, OR, 4Bristol-Myers Squibb, Princeton, NJ, 5University of Alabama at Birmingham, Birmingham, AL, 6Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, 7Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 8Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Current guidelines recommend holding biologic DMARDs before major surgery, despite limited data. Few studies have examined perioperative timing of individual biologic therapies. This study…
  • Abstract Number: 527 • 2017 ACR/ARHP Annual Meeting

    Cardiovascular Safety of Tocilizumab Versus Abatacept in Patients with Rheumatoid Arthritis: A Multi-Database Study

    Seoyoung C. Kim1, Daniel H. Solomon1, James R. Rogers2, Sara Gale3, Micki Klearman3, Khaled Sarsour3 and Sebastian Schneeweiss2, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Genentech, South San Francisco, CA

    Background/Purpose: While tocilizumab (TCZ) may increase serum lipid levels, recent studies do not suggest an increased cardiovascular (CV) risk associated with TCZ use compared to…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology